Wedbush Maintains Outperform on Design Therapeutics, Raises Price Target to $26
Wedbush analyst Laura Chico maintains Design Therapeutics (NASDAQ:DSGN) with a Outperform and raises the price target from $21 to $26.
Wedbush Initiates Coverage On Design Therapeutics with Outperform Rating, Announces Price Target of $21
Wedbush analyst Laura Chico initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a Outperform rating and announces Price Target of $21.
Goldman Sachs Maintains Sell on Design Therapeutics, Lowers Price Target to $6
Goldman Sachs maintains Design Therapeutics (NASDAQ:DSGN) with a Sell and lowers the price target from $8 to $6.
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows.
RBC Capital Initiates Coverage On Design Therapeutics with Outperform Rating, Announces Price Target of $30
RBC Capital initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a Outperform rating and announces Price Target of $30.
Design Therapeutics Completes Dosing In First Patient Cohort Of Phase 1 Trial Of DT-216 GeneTAC™ Molecule For The Treatment Of Friedreich Ataxia
Topline Data from Phase 1 Trial Expected in the Second Half of 2022
DT-216 Granted FDA Fast Track Designation for Patients with Friedreich Ataxia
CARLSBAD, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Design
Design Therapeutics Announces FDA Clearance Of Investigational New Drug Application For First GeneTAC Molecule For Friedreich Ataxia
Phase 1 Trial of DT-216 in Patients with Friedreich Ataxia to Be Initiated Soon
Topline Data from Phase 1 Trial Expected in the Second Half of 2022
CARLSBAD, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Design
Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating
Goldman Sachs initiated cov
46 Biggest Movers From Yesterday
Gainers
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) gained 34.1% to settle at $12.58 on Wednesday.